21Vianet Group, e.l.f. Beauty, Gilead Sciences Stocks Moving Today

Three stocks making big moves on the charts today are 21Vianet Group Inc (VNET), e.l.f. Beauty Inc (ELF), and Gilead Sciences, Inc. (GILD)

Mar 9, 2017 at 3:10 PM
facebook X logo linkedin


Stocks are struggling on falling oil prices, with tomorrow's key jobs report on tap. Among specific equities in focus are internet stock 21Vianet Group Inc (NASDAQ:VNET), cosmetics maker e.l.f. Beauty Inc (NYSE:ELF), and drugmaker Gilead Sciences, Inc. (NASDAQ:GILD). Here's a quick look at what's moving shares of VNET, ELF, and GILD.

Earnings Send 21Vianet Group Shares to Record Lows

VNET is among the worst performers on the Nasdaq today, down 18.9% at $5.72 after earlier notching an all-time low of $5.69. Weighing on the shares is the company's disappointing earnings report, which was met with a price-target cut to $7.50 from $9 at Stifel. 21Vianet is no stranger to losses, having surrendered 71.3% over the past 12 months. As such, it's not surprising analysts have been skeptical. Only two firms currently follow the stock, and both recommend holding or selling the shares. 

e.l.f. Beauty Beats on Top and Bottom Lines

A trip to the earnings confessional proved kind to market newcomer ELF, with the shares among the top gainers on the New York Stock Exchange. Specifically, the stock is trading up 12.3% at $28.40, after the company beat expectations for earnings and revenue and gave an upbeat outlook. Morgan Stanley, Cowen, and BMO all chimed in with price-target hikes, with the latter setting the highest bar at $38 -- deep into never-before-seen territory. Though e.l.f. Beauty Inc only began trading publicly in late September, short sellers have wasted no time piling on board. Nearly four-fifths of the stock's total float is wrapped up in these bearish bets, accounting for 6.7 sessions' worth of trading, at ELF's typical daily pace.

Bearish Brokerage Note Smacks Gilead Sciences

Analysts at UBS lowered their rating on GILD to "neutral" from "buy," and their price target to $72 from $118, citing poor sales for the company's hepatitis C treatments. The shares are down 2.3% at $68.11, and could see further trouble, should more brokerages follow suit. As of last night's close, 11 firms had doled out "buy" or better ratings on Gilead Sciences, Inc., compared to eight "holds" and not a single "sell." Downgrades seem long overdue, too, considering the stock has shed nearly one-quarter of its value year-over-year, with the declining 20-week moving average pressuring GILD lower since last spring.

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI